Lilly, Daiichi Submit Clot-Blocker for U.S. Approval |
| Bloomberg - Jan 4, 2008 |
Eli Lilly & Co. and Daiichi Sankyo asked U.S. regulators to approve prasugrel, their experimental clot-blocking drug to prevent heart attacks.
Lilly, of Indianapolis, and Japan-based Daiichi filed an application with the Food and Drug Administration, the companies said today in a statement. While prasugrel, to be sold under the name Effient, prevented more heart attacks and strokes than Plavix, the top-selling blood-thinning drug, in a study, more patients died from fatal bleeding.
The mixed results of the trial, reported last month, caused analysts to back away from estimates that prasugrel could generate as much as $4 billion a year in peak sales. The drug may bring in $75 million in 2008, $375 million in 2009 and $900 million in 2011, analyst Mario Corso of Summer Street Research Partners said in a note to clients.
Read Full Article from Bloomberg
- Posted: 2008-01-04 09:19:58
| More Stock Investor Place Financial News |
 |
|
|
|
| Stock Investor Place Financial News Archive |
|
|
|
